Back
Compare AU
Compare DBBF vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Ethical Diversified Balanced ETF (DBBF) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DBBF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 8 | 65 |
Median incremental investment | $2,804.75 | $865.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,094.64 | $1,950.63 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DBBF | DRUG | |
|---|---|---|
Strategy | DBBF.AX was created on 2019-12-15 by BetaShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. DBBF.AX aims to provide exposure to a cost-effective, multi-asset class portfolio, for investors whose priority is investing in a way that aligns with their values. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BETASHARES ETHICAL AUSTRALIAN (29.96 %) BETASHARES AUSTRALIAN SUSTAINA (20.74 %) BETASHARES GLOBAL SUSTAINABILI (20.42 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (99.83 %) Communication Services (0.17 %) | Other (76.26 %) Communication Services (33.53 %) Health Care (23.55 %) |
Top 3 countries | United States (49.53 %) Australia (33.94 %) Japan (4.68 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.26 % | 0.57 % |
Key Summary
DBBF | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.26 % | 0.57 % |
Price | $26.27 | $7.59 |
Size | $33.932 million | $173.344 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.63 % | 1.89 % |
Market | ASX | ASX |
First listed date | 11/12/2019 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DBBF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 8 | 65 |
Median incremental investment | $2,804.75 | $865.32 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,094.64 | $1,950.63 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DBBF | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DBBF | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |